The pivotal role of intracellular calcium in oxaliplatin-induced inhibition of neurite outgrowth but not cell death in differentiated PC12 cells

Chemical Research in Toxicology

Volumn 24, Issue 11, 2011, Pages 1845-1852

  Takeshita, Miki ^a   Banno, Yoshiko ^b   Nakamura, Mitsuhiro ^a   Otsuka, Mayuko ^a   Teramachi, Hitomi ^a   Tsuchiya, Teruo ^a   Itoh, Yoshinori ^c  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c GIFU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ELPLAT; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; GLUCONATE CALCIUM; MAGNESIUM SULFATE; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; NEUROMODULIN; OXALIC ACID; OXALIPLATIN; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CELL LEVEL; CANCER CELL CULTURE; CELL DEATH; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; NERVE CELL INHIBITION; NEURITE; NEUROPROTECTION; NEUROTOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM; CALCIUM GLUCONATE; CELL DEATH; CELL DIFFERENTIATION; CHELATING AGENTS; EGTAZIC ACID; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GAP-43 PROTEIN; GENE EXPRESSION; HCT116 CELLS; HUMANS; MAGNESIUM SULFATE; NEOPLASMS; NERVE GROWTH FACTOR; NEURITES; ORGANOPLATINUM COMPOUNDS; OXALIC ACID; PC12 CELLS; RATS; SIGNAL TRANSDUCTION;

EID: 81755176468     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx200160g     Document Type: Article

References (55)

1. Misset, J. L. (1998) Oxaliplatin in practice Br. J. Cancer 77 (Suppl. 4) 4-7
2. André, T., Bensmaine, M. A., Louvet, C., François, E., Lucas, V., Desseigne, F., Beerblock, K., Bouché, O., Carola, E., Merrouche, Y., Morvan, F., Dupont-André, G., and de Gramont, A. (1999) Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen J. Clin. Oncol. 17, 3560-3568 (Pubitemid 29517928)
3. Maindrault-Goebel, F., Louvet, C., André, T., Carola, E., Lotz, J. P., Molitor, J. L., Garcia, M. L., Gilles-Amar, V., Izrael, V., Krulik, M., and de Gramont, A. (1999) Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR Eur. J. Cancer 35, 1338-1342 (Pubitemid 29397433)
4. de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., Papamichael, D., Le Bail, N., Louvet, C., Hendler, D., de Braud, F., Wilson, C., Morvan, F., and Bonetti, A. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J. Clin. Oncol. 18, 2938-2947 (Pubitemid 30644117)
5. Piccart, M. J., Green, J. A., Lacave, A. J., Reed, N., Vergote, I., Benedetti-Panici, P., Bonetti, A., Kristeller-Tome, V., Fernandez, C. M., Curran, D., Van Glabbeke, M., Lacombe, D., Pinel, M. C., and Pecorelli, S. (2000) Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group J. Clin. Oncol. 18, 1193-1202 (Pubitemid 30159836)
6. Fracasso, P. M., Blessing, J. A., Wolf, J., Rocereto, T. F., Berek, J. S., and Waggoner, S. (2003) Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: A gynecologic oncology group study Gynecol. Oncol. 90, 177-180 (Pubitemid 37338094)
7. Dong, N., Jiang, W., Li, H., Liu, Z., Xu, X., and Wang, M. (2009) Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer Am. J. Clin. Oncol. 32, 559-563
8. Kaechele, V., Moehler, M., Lutz, M. P., von Wichert, G., Eisele, M., Klaus, J., Galle, P. R., Adler, G., and Seufferlein, T. (2010) A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: A study of the Arbeitsgemeinschaft Internistische Onkologie Cancer Chemother. Pharmacol. 66, 191-195
9. Monnet, I., Brienza, S., Hugret, F., Voisin, S., Gastiaburu, J., Saltiel, J. C., Soulié, P., Armand, J. P., Cvitkovic, E., and de Cremoux, H. (1998) Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC) Eur. J. Cancer 34, 1124-1127 (Pubitemid 28308357)
10. Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M., Aitini, E., Taïeb, J., Faroux, R., Lepere, C., and de Gramont, A. (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial J. Clin. Oncol. 23, 3509-3516
11. Bokemeyer, C., Oechsle, K., Honecker, F., Mayer, F., Hartmann, J. T., Waller, C. F., Böhlke, I., and Kollmannsberger, C. (2008) Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: A study of the German Testicular Cancer Study Group Ann. Oncol. 19, 448-453 (Pubitemid 351325663)
12. Sharma, A., Mohanti, B., Raina, V., Shukla, N., Pal, S., Dwary, A., Deo, S., Sahni, P., Garg, P., Thulkar, S., DattaGupta, S., and Rath, G. (2010) A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer Cancer Chemother. Pharmacol. 65, 497-502
13. Extra, J. M., Espie, M., Calvo, F., Ferme, C., Mignot, L., and Marty, M. (1990) Phase I study of oxaliplatin in patients with advanced cancer Cancer Chemother. Pharmacol. 25, 299-303 (Pubitemid 20014976)
14. Wilson, R. H., Lehky, T., Thomas, R. R., Quinn, M. G., Floeter, M. K., and Grem, J. L. (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability J. Clin. Oncol. 20, 1767-1774 (Pubitemid 34273265)
15. Lehky, T. J., Leonard, G. D., Wilson, R. H., Grem, J. L., and Floeter, M. K. (2004) Oxaliplatin-induced neurotoxicity: Acute hyperexcitability and chronic neuropathy Muscle Nerve 29, 387-392 (Pubitemid 38269758)
16. Argyriou, A. A., Polychronopoulos, P., Iconomou, G., Koutras, A., Makatsoris, T., Gerolymos, M. K., Gourzis, P., Assimakopoulos, K., Kalofonos, H. P., and Chroni, E. (2007) Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer Acta Oncol. 46, 1131-1137 (Pubitemid 350058888)
17. Park, S. B., Lin, C. S., Krishnan, A. V., Goldstein, D., Friedlander, M. L., and Kiernan, M. C. (2009) Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy Brain 132 (Part 10) 2712-2723
18. Adelsberger, H., Quasthoff, S., Grosskreutz, J., Lepier, A., Eckel, F., and Lersch, C. (2000) The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons Eur. J. Pharmacol. 406, 25-32
19. Krishnan, A. V., Goldstein, D., Friedlander, M., and Kiernan, M. C. (2006) Oxaliplatin and axonal Na+ channel function in vivo Clin. Cancer Res. 12, 4481-4484 (Pubitemid 44297795)
20. Grolleau, F., Gamelin, L., Boisdron-Celle, M., Lapied, B., Pelhate, M., and Gamelin, E. (2001) A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels J. Neurophysiol. 85, 2293-2297 (Pubitemid 32440704)
21. Webster, R. G., Brain, K. L., Wilson, R. H., Grem, J. I., and Vincent, A. (2005) Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels Br. J. Pharmacol. 146, 1027-1039 (Pubitemid 41722176)
22. Argyriou, A. A., Polychronopoulos, P., Iconomou, G., Chroni, E., and Kalofonos, H. P. (2008) A review on oxaliplatin-induced peripheral nerve damage Cancer Treat. Rev. 34, 368-377
23. Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M., Beretta, G. D., Ubiali, E., and Catalano, G. (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial J. Clin. Oncol. 20, 3478-3483
24. Lersch, C., Schmelz, R., Eckel, F., Erdmann, J., Mayr, M., Schulte-Frohlinde, E., Quasthoff, S., Grosskreutz, J., and Adelsberger, H. (2002) Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer Clin. Colorectal Cancer 2, 54-58 (Pubitemid 34704965)
25. von Delius, S., Eckel, F., Wagenpfeil, S., Mayr, M., Stock, K., Kullmann, F., Obermeier, F., Erdmann, J., Schmelz, R., Quasthoff, S., Adelsberger, H., Bredenkamp, R., Schmid, R. M., and Lersch, C. (2007) Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study Invest. New Drugs 25, 173-180 (Pubitemid 46020877)
26. Durand, J. P., Alexandre, J., Guillevin, L., and Goldwasser, F. (2005) Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy Anticancer Drugs 16, 587-591 (Pubitemid 40685744)
27. Ghirardi, O., Lo Giudice, P., Pisano, C., Vertechy, M., Bellucci, A., Vesci, L., Cundari, S., Miloso, M., Rigamonti, L. M., Nicolini, G., Zanna, C., and Carminati, P. (2005) Acetyl- l -carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties Anticancer Res. 25, 2681-2687
28. Lin, P. C., Lee, M. Y., Wang, W. S., Yen, C. C., Chao, T. C., Hsiao, L. T., Yang, M. H., Chen, P. M., Lin, K. P., and Chiou, T. J. (2006) N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: Preliminary data Support Care Cancer 14, 484-487
29. Saif, M. W. and Hashmi, S. (2008) Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer Cancer Chemother. Pharmacol. 61, 349-354 (Pubitemid 350275990)
30. Amara, S. (2008) Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy Ann. Pharmacother. 42, 1481-1485
31. Shindo, Y., Tenma, K., Imano, H., Hibino, M., Yoshino, K., and Nakamura, M. (2008) Reduction of oxaliplatin-related neurotoxicity by Gosha-jinki-gan Gan To Kagaku Ryoho 35, 863-865
32. Gamelin, L., Boisdron-Celle, M., Delva, R., Guerin-Meyer, V., Ifrah, N., Morel, A., and Gamelin, E. (2004) Prevention of oxaliplatin-related neurotoxicity by Ca/Mg infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer Clin. Cancer Res. 10, 4055-4061 (Pubitemid 38812481)
33. Gamelin, L., Capitain, O., Morel, A., Dumont, A., Traore, S., Annel, le B., Gilles, S., Biosdron-Celle, M., and Gamelin, E. (2007) Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway Clin. Cancer Res. 13, 6359-6368 (Pubitemid 350075025)
34. Hochster, H. S., Grothey, A., and Childs, B. (2007) Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity J. Clin. Oncol. 25, 4028a-4029a
35. Gamelin, L., Boisdron-Celle, M., Morel, A., Poirier, A. L., Berger, V., Gamelin, E., Tournigand, C., and de Gramont, A. (2008) Oxaliplatin-related neurotoxicity: Interest of calcium-magnesium infusion and no impact on its efficacy J. Clin. Oncol. 26, 1188-1189
36. Das, K. P., Freudenrich, T. M., and Mundy, W. R. (2004) Assessment of PC12 cell differentiation and neurite growth: A comparison of morphological and neurochemical measures Neurotoxicol. Teratol. 26, 397-406 (Pubitemid 38534472)
37. 2, but not by carbachol, in rat pheochromocytoma PC12 cells J. Neurochem. 71, 2278-2285 (Pubitemid 28531237)
38. Wooten, M. W., Zhou, G., Seibenhener, M. L., and Cohen, E. S. (1994) A role for zeta protein kinase C in nerve growth factor-induced differentiation of PC12 cells Cell Growth Differ. 5, 395-403 (Pubitemid 24251390)
39. Pang, L., Sawada, T., Decker, S. J., and Saltiel, A. R. (1995) Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor J. Biol. Chem. 270, 13585-13588
40. Boglári, G., Erhardt, P., Cooper, G. M., and Szeberényi, J. (1998) Intact Ras function is required for sustained activation and nuclear translocation of extracellular signal-regulated kinases in nerve growth factor-stimulated PC12 cells Eur. J. Cell Biol. 75, 54-58 (Pubitemid 28080647)
41. Dickson, B. J. (2001) Rho GTPase in growth cone guiance Curr. Opin. Neurol. Biol. 11, 103-110 (Pubitemid 32155956)
42. Etienne-Manneville, S. and Hall, A. (2002) Rho GTPase in cell biology Nature 420, 629-635
43. 2+-dependent regulation of Rho GTPases triggers turning of nerve growth factor J. Neurosci. 25, 2338-2347 (Pubitemid 40322275)
44. Nikodijevic, B. and Guroff, G. (1991) Nerve growth factor-induced increase in calcium-uptake by PC12 cells J. Neurosci. Res. 28, 192-199
45. Kater, S. B., Mattson, M. P., Cohan, C., and Connor, J. (1988) Calcium regulation of the neuronal growth cone Trends Neurosci. 11, 315-321
46. Banno, Y., Nemoto, S., Murakami, M., Kimura, M., Ueno, Y., Ohguchi, K., Hara, A., Okano, Y., Kitade, Y., Onozuka, M., Murate, T., and Nozawa, Y. (2008) Depolarization-induced differentiation of PC12 cells is mediated by phospholipase D2 through the transcription factor CREB pathway J. Neurochem. 104, 1372-1386 (Pubitemid 351293345)
47. Vaudry, D., Stork, P. J., Lazavoid, P., and Eiden, L. E. (2002) Signaling pathways for PC12 cell differentiation: Making the right connections Science 296, 1648-1649 (Pubitemid 34579153)
48. Diolaiti, D., Bernardoni, R., Trazzi, S., Papa, A., Porro, A., Bono, F., Herbert, J. M., Perini, G., and Della Valle, G. (2007) Functional cooperation between TrkA and p75(NTR) accelerates neuronal differentiation by increased transcription of GAP-43 and p21(CIP/WAF) genes via ERK1/2 and AP-1 activities Exp. Cell Res. 313, 2980-2992 (Pubitemid 47125888)
49. Scuteri, A., Galimberti, A., Ravasi, M., Pasini, S., Donzelli, E., Cavaletti, G., and Tredici, G. (2010) NGF protects dossal root ganglion neurons from oxaliplatin by modulating JNK/Sapk and ERK1/2 Neurosci. Lett. 486, 141-145
50. Sakurai, M., Egashira, N., Kawashiri, T., Yano, T., Ikesue, H., and Oishi, R. (2009) Oxaliplatin-induced neuropathy in the rat: Involvement of oxalate in cold hyperalgesia but not mechanical allodynia Pain 147, 165-174
51. Anand, U., Otto, W. R., and Anand, P. (2010) Sensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons Mol. Pain 6, 82-93
52. Hansen, T. V. O., Rehfeld, J. F., and Nielsen, F. C. (2003) KCl potentiates forskolin-induced PC12 cells neurite outgrowth via protein kinase A and extracellular signal-regulated kinase signaling pathways Neurosci. Lett. 347, 57-61 (Pubitemid 36831106)
53. Di Francesco, A. M., Ruggiero, A., and Riccardi, R. (2002) Cellular and molecular aspects of drugs of the future: Oxaliplatin Cell. Mol. Life Sci. 59, 1914-1927 (Pubitemid 36015864)
54. Kasparkova, J., Vojtiskova, M., Natile, G., and Brabec, V. (2008) Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand Chemistry 14, 1330-1341 (Pubitemid 351204614)
55. Tan, Z., Dohi, S., Chen, J., Banno, Y., and Nozawa, Y. (2002) Involvement of the mitogen-activated protein kinase family in tetracaine-induced PC12 cell death Anesthesiology 96, 1191-1201 (Pubitemid 34462582)